GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » Notes Receivable

Zevra Therapeutics (FRA:1GDA) Notes Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Notes Receivable?

Zevra Therapeutics's Notes Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.

Zevra Therapeutics's quarterly Notes Receivable declined from Sep. 2023 (€39.35 Mil) to Dec. 2023 (€0.00 Mil) but then stayed the same from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).


Zevra Therapeutics Notes Receivable Historical Data

The historical data trend for Zevra Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Notes Receivable Chart

Zevra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zevra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 39.35 - -

Zevra Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Zevra Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics (FRA:1GDA) Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines